doi: 10.3390/antiox13040429 113 KashiDSShabirADa BoitMBaileySJHigginsMF
In recent years, dual agonists of the incretin system have been tested in pre-clinical and early-phase clinical trials, with the glucose-dependent insulinotropic polypeptide and GLP-1 co-agonist, tirzepatide, recently approved for clinical use
Wexler DJ (2020): Initial management of hyperglycemia in adults with type 2 diabetes mellitus
PlexusDx does not sell, distribute, prescribe, endorse, or recommend the peptide discussed here or any therapeutic or research peptide in this category several such compounds are not approved for human use in the United States
If you're planning on ending your GLP-1 drug use someday, the last thing you want is to lose all your progress